Incidence of Serious Gastrointestinal Events and Inflammatory Bowel Disease Among Tildrakizumab-Treated Patients with Moderate to Severe Plaque Psoriasis: Data from 3 Large Randomized Clinical Trials

Incidence of Serious Gastrointestinal Events and Inflammatory Bowel Disease Among Tildrakizumab-Treated Patients with Moderate to Severe Plaque Psoriasis: Data from 3 Large Randomized Clinical Trials Meeting Abstract

sustainable development goals

SDG 03: Good Health and Well-being

publication date

September 1, 2018

webpage

Web of Science

published in

ARTHRITIS & RHEUMATOLOGY Journal

volume

70